Target Name: MIOX
NCBI ID: G55586
Review Report on MIOX Target / Biomarker Content of Review Report on MIOX Target / Biomarker
MIOX
Other Name(s): kidney-specific protein 32 | aldehyde reductase (aldose reductase) like 6 | Renal-specific oxidoreductase | Kidney-specific protein 32 | Myo-inositol oxygenase | Inositol oxygenase | myo-inositol oxygenase | RSOR | ALDRL6 | renal-specific oxidoreductase | aldehyde reductase-like 6 | MIOX_HUMAN | KSP32 | MI oxygenase | Aldehyde reductase-like 6 | inositol oxygenase

Discovering MIOX: A Potential Drug Target Or Biomarker for Kidney Diseases

MIOX (Kidney-Specific Protein 32) is a protein that is expressed in the kidney, specifically in the glomeruli, and it is considered as a potential drug target or biomarker. The discovery of MIOX as a potential drug target or biomarker has significant implications for the treatment of kidney diseases, such as diabetic nephropathy, chronic kidney disease, and several other renal diseases.

MIOX is a 32-kDa protein that is expressed in the kidney, specifically in the glomeruli. It is a member of the superfamily of proteins known as the immunoglobulin-like error-converting enzyme (IEC) family 3 (IEC-3) and is characterized by the presence of a single transmembrane domain and a cytoplasmic tail. MIOX is a unique protein that is expressed only in the kidney and is expressed at different levels in other tissues, such as the liver, heart, and brain.

MIOX is involved in several physiological processes in the kidney, including filtering blood, removing waste products, and maintaining the proper balance of ions and solutes in the body. It is a key protein that plays a critical role in maintaining the health and function of the kidney.

MIOX has been identified as a potential drug target due to its unique expression pattern in the kidney and its involvement in several physiological processes that are important for kidney health. Several studies have shown that MIOX is involved in several diseases, including diabetes, chronic kidney disease, and neurodegenerative diseases.

In the context of diabetes, MIOX has been shown to be involved in the regulation of immune cell function and has been identified as a potential target for anti-diabetic drugs. Several studies have shown that MIOX interacts with drugs such as statins, which are used to treat diabetes, and that MIOX modulates the immune response to these drugs.

In the context of chronic kidney disease, MIOX has been shown to be involved in the regulation of fibrosis and has been identified as a potential target for anti-fibrotic drugs. Several studies have shown that MIOX can inhibit the activation and proliferation of fibroblasts and that these effects are dependent on the levels of MIOX in the kidney.

In the context of neurodegenerative diseases, MIOX has been shown to be involved in the regulation of neurotransmitter synthesis and has been identified as a potential target for drugs that treat neurodegenerative diseases. Several studies have shown that MIOX can modulate the levels of neurotransmitters, such as dopamine and glutamate, in the brain and that these effects are dependent on the levels of MIOX in the brain.

MIOX is a unique protein that is expressed only in the kidney and has been shown to be involved in several physiological processes that are important for kidney health. Its potential as a drug target or biomarker makes it an attractive target for researchers to study and develop new treatments for kidney diseases. Further studies are needed to fully understand the role of MIOX in the regulation of kidney health and to determine its potential as a drug target or biomarker.

Protein Name: Myo-inositol Oxygenase

The "MIOX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIOX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B